ru24.pro
News in English
Декабрь
2024

Новости за 04.12.2024

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial - CNBC

Top Stories (us) - Google News (ru) 

  1. Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial  CNBC
  2. Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study  The Wall Street Journal
  3. Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal  MarketWatch
  4. Zepbound leads to more weight loss than Wegovy, study finds  ABC News

Time to Rethink Automotive Regulations

Wardsauto.com 

Instead of different agencies writing rules that duplicate what’s being done, or even conflict with each other, why not have one office of automotive regulation?

Lilly beats Novo in bellwether head-to-head weight loss study - Endpoints News

Google.com 

  1. Lilly beats Novo in bellwether head-to-head weight loss study  Endpoints News
  2. Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial  CNBC
  3. Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%  Investors | Eli Lilly and Company
  4. Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head... Читать дальше...

5 Ways AI Enhances Maintenance Team Efficiency

Forbes.com 

A data-driven approach can set modern maintenance teams apart, helping them see preexisting maintenance activities while also simulating future maintenance needs.

No FA action over second Guéhi 'Jesus' armband

ESPN FC: Adelaide United 

The FA will again remind Crystal Palace defender Marc Guéhi about kit regulations but he will face no formal action after writing "Jesus loves you" on his rainbow-coloured captain's armband